4　その他
⑴　契約手続において使用する言語及び通貨　日本語及び日本国通貨。
⑵　入札保証金及び契約保証金　免除。
⑶　入札者に要求される事項　この一般競争に参加を希望する者は、封印した入札書に本公告に示した物品を納入できることを証明する書類を添付して入札書の受領期限までに提出しなければならない。入札者は、開札日の前日までの間において、分任契約担当役から当該書類に関し説明を求められた場合は、それに応じなければならない。
⑷　入札の無効　本公告に示した競争参加資格のない者の提出した入札書、入札者に求められる義務を履行しなかった者の提出した入札書、その他入札説明書による。
⑸　契約書作成の要否　要。
⑹　落札者の決定方法　本公告に示した物品又はこれと同等のものを納入できると分任契約担当役が判断した入札者であって、国立大学法人筑波大学財務規則施行規程第53条の規定に基づいて作成された予定価格の制限の範囲内で最低価格をもって有効な入札を行った入札者を落札者とする。
⑺　手続における交渉の有無　無。
⑻　その他　詳細は、入札説明書による。なお、入札説明書等で当該調達に関する環境上の条件を定めた調達であると示されている場合は、十分理解した上で応札すること。
5　Summary
⑴　Official in charge of disbursement of the procuring entity : HIRAMASTU Yuji, The Obligating Officer Director, University of Tsukuba Hospital
⑵　Classification of the products to be procured : 4
⑶　Nature and quantity of the products to be purchased :
A　Pembrolizumab (Genetical Recombination) 100mg／4mL 1vial／case about 3560cases
B　Nivolumab (Genetical Recombination) 240mg／24mL 1vial／case about 1620cases
C　Vutrisiran Sodium 25mg／0.5mL 1syringe／case about 20cases
D　Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial／case about 580cases
E　Efgartigimod Alfa (Genetical Recombination) 400mg／20mL 1vial／case about 650cases
F　Durvalumab (Genetical Recombination) 500mg／10mL 1vial／case about 720cases
G　Elranatamab (Genetical Recombination) 76mg／1.9mL 1vial／case about 190cases
H　Teprotumumab (Genetical Recombination) 500mg 1vial／case about 190cases
I　Epcoritamab (Genetical Recombination) 48mg／0.8mL 1vial／case about 60cases
J　Ipilimumab (Genetical Recombination) 50mg／10mL 1vial／case about 250cases
K　Amivantamab (Genetical Recombination) 350mg／7mL 1vial／case about 390cases
L　Risankizumab (Genetical Recombination) 150mg ／ 1mL 1syringe ／ case about 330cases
M　Paclitaxel 100mg 1vial／case about 3230cases
N　Canakinumab (Genetical Recombination) 150mg／1mL 1vial／case about 70cases
O　Risankizumab (Genetical Recombination) 360mg／2.4mL 1kit／case about 200cases
P　Trastuzumab Deruxtecan (Genetical Recombination) 100mg 1vial／case about 540cases
Q　Lenalidomide Hydrate 5mg 40capsules／case about 320cases
R　Atezolizumab (Genetical Recombination) 1200mg／20mL 1vial／case about 190cases
S　Blinatumomab (Genetical Recombination) 35μg　1vial／case about 270cases
T　Aflibercept (Genetical Recombination) 40mg 1syringe／case about 1040cases
U　Efgartigimod Alfa (Genetical Recombination) ・Vorhyaluronidase Alfa (Genetical Recombination) 5mg 1syringe／case about 150cases
V　Avelumab (Genetical Recombination) 200mg 1vial／case about 730cases
W　Avalglucosidase Alfa (Genetical Recombination) 100mg 1vial／case about 520cases
X　Sotatercept (Genetical Recombination) 45mg 1vial／case about 80cases
Y　Aflibercept (Genetical Recombination) 8mg 1syringe／case about 510cases
Z　Datopotamab Deruxtecan (Genetical Recombination) 100mg 1vial／case about 170cases
AA　Sacituzumab Govitecan (Genetical Recombination) 200mg 1vial／case about 330cases
AB　Nirsevimab (Genetical Recombination) 50mg ／ 0.5mL 1syringe ／ case about 160cases
AC　Polyethylene Glycol Treated Human Normal Immunoglobulin 10g ／ 100mL 1vial／case about 790cases
AD　Faricimab (Genetical Recombination) 6mg／0.05mL 1syringe／case about 530cases
AE　Letermovir 240mg 14tablets／case about 350cases
AF　Romiplostim (Genetical Recombination) 250μg　1vial／case about 1440cases
AG　Irinotecan Hydrochloride Hydrate 43mg／10mL 1vial／case about 530cases
AH　pH4-Treated Normal Human Immunoglobulin 10g／100mL 1vial／case about 520cases
AI　Enfortumab Vedotin (Genetical Recombination) 30mg 1vial ／ case about 850cases
AJ　Brentuximab Vedotin (Genetical Recombination) 50mg 1vial ／ case about 180cases
AK　Infliximab (Genetical Recombination) 100mg 1vial／case about 1270cases
AL　Denosumab (Genetical Recombination) 120mg ／ 1mL 1syringe ／ case about 1210cases
AM　Evinacumab (Genetical Recombination) 345mg／2.3mL 1vial／case about 40cases
AN　Ramucirumab (Genetical Recombination) 500mg ／ 50mL 1vial ／ case about 160cases
AO　Tarlatamab (Genetical Recombination) 10mg 1vial／case about 40cases
AP　Trastuzumab Emtansine (Genetical Recombination) 100mg 1vial／case about 170cases
AQ　Pegfilgrastim (Genetical Recombination) 3.6mg ／ 0.36mL 1kit ／ case about 600cases
AR　pH4-Treated Normal Human Immunoglobulin 20g／200mL 1vial／case about 270cases
AS　Tremelimumab (Genetical Recombination) 300mg ／ 15mL 1vial ／ case about 10cases
AT　Ustekinumab (Genetical Recombination) 45mg ／ 0.5mL 1syringe/case about 280cases
AU　Abatacept (Genetical Recombination) 250mg 1vial／case about 860cases
AV　Maribavir 200mg 28tablets ／ case about 30cases
AW　Inebilizumab (Genetical Recombination) 100mg／10mL 3vials／case about 5cases
AX　Cetuximab (Genetical Recombination) 100mg／20mL 1vial／case about 1750cases
AY　Guselkumab (Genetical Recombination) 100mg ／ 1mL 1syringe ／ case about 130cases
AZ　Fosnetupitant Chloride Hydrochloride 235mg 5vials／case about 690cases
BA　Zolbetuximab (Genetical Recombination) 100mg 1vial／case about 760cases
BB　Obinutuzumab (Genetical Recombination) 1000mg ／ 40mL 1vial ／ case about 120cases
BC　Leuprorelin Acetate 11.25mg 1syringe／case about 900cases
BD　Nirsevimab (Genetical Recombination) 100mg ／ 1mL 1syringe ／ case about 50cases